A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: Valorisation and improving the tech transfer cycle
详细信息 查看全文
- 作者：M. van den Nieuwboer ; m.vanden.nieuwboer@vu.nl" class="auth_mail" title="E-mail the corresponding author ; L.H.M. van de Burgwal ; E. Claassen
- 关键词：AAD ; antibiotic-associated diarrhoea ; AD ; atopic dermatitis ; CMC ; chemistry ; CT ; clinical trial ; EFSA ; European food safety authority ; GIT ; gastrointestinal tract ; GRAS ; generally recognized as safe ; IBD ; inflammatory bowel disease ; IBS ; irritable bowel syndrome ; IND ; investigational new drug ; KOL ; key-opinion-leader ; MD ; medical doctor ; NEC ; necrotizing enterocolitis ; QPS ; qualified presumption of safety ; R&D ; research & development ; UC ; ulcerative colitis
- 刊名：PharmaNutrition
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：4
- 期：1
- 页码：9-18
- 全文大小：2094 K
文摘
- •
Innovation cycle of probiotics is faulty.
- •
Barriers hampering the innovation process at all domains in the cycle.
- •
Difficulty in demonstrating clinical efficacy is most important barrier.
- •
Eleven main barriers were identified.
- •
Serious efforts are required to restore the natural innovation cycle.